Upstream Bio receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | UPB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUPBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −1.6x | −0.2x | |
PEG Ratio | −0.28 | −0.05 | 0.00 | |
Price/Book | 0.7x | 2.4x | 2.6x | |
Price / LTM Sales | 64.2x | 13.3x | 2.8x | |
Upside (Analyst Target) | - | 113.6% | 62.7% | |
Fair Value Upside | Unlock | 26.0% | 8.0% | Unlock |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.